-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fatty acid binding protein (FABP) is a group of intracellular chaperone molecules involved in lipid-mediated processes
.
FABPs are considered to be key mediators of metabolic and inflammatory pathways
Fatty acid binding protein (FABP) is a group of intracellular chaperone molecules involved in lipid-mediated processes
The researchers divided the prospective cohort of 444 patients hospitalized with DC into a study cohort (305 patients) and a verification cohort (139 patients)
.
L-FABP was measured in urine and plasma samples collected on admission
In univariate analysis, L-FABP in urine rather than plasma was associated with the 3-month survival rate of DC patients
.
In multivariate analysis, uL-FABP and the end-stage liver disease sodium model (MELDNa) are the only independent predictors of prognosis
This study confirmed that in terms of mortality and ACLF development, UL-FABP levels are independently related to the 3-month clinical course of DC patients
.
If the urine L-FABP and MELDNa scores are combined, it seems to be a better biomarker candidate for DC prognosis prediction
This study confirmed that in terms of mortality and ACLF development, UL-FABP levels are independently related to the 3-month clinical course of DC patients
Original source:
Adrià Juanola.
Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
Leave a message here